Nov 6 (Reuters) - Bristol Myers Squibb has acquired Orum’s experimental therapy to treat patients with a type of blood cancer for a total value of up to $180 million, Orum said on Monday. (Reporting by Khushi Mandowara in Bengaluru; Editing by Dhanya Ann Thoppil)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.8 USD | -0.69% | -2.55% | -14.65% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.65% | 89.42B | |
+32.01% | 694B | |
+29.39% | 593B | |
-1.59% | 371B | |
+20.00% | 331B | |
+6.99% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.05% | 169B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol Myers Squibb buys Orum's blood cancer therapy for up to $180 mln